CJC-1295

Also known as: CJC-1295 no DAC, Modified GRF 1-29, Mod GRF

Growth HormonePHASE 2

Clinical Status

Investigational — Phase II trial discontinued.

Mechanism of Action

Binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. Without DAC, half-life is about 30 minutes. Often combined with a GHRP like Ipamorelin for synergistic effects.

Dosing Defaults

Dose

100 mcg

Frequency

1x daily

Administration

Subcutaneous injection

Timing

Before bed

Food

fasted

Duration

8-12 weeks

Dose range: 100-300 mcg per dose

Evening dosing supports natural GH patterns during sleep.

Side Effects

•Injection site reactions
•Facial flushing
•Headache
•Water retention
•Dizziness
•May trigger histamine release

Contraindications & Warnings

⚠Active malignancy

•Not medical advice

Compare

Compare CJC-1295 with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your CJC-1295 dose.

Open Calculator

Related Growth Hormone Peptides

Ipamorelin

PHASE 2

Growth Hormone

Selective GH secretagogue. Considered one of the safest GHRPs.

CJC-1295 DAC

PHASE 2

Growth Hormone

Long-acting version of CJC-1295 with extended half-life via albumin binding.

Tesamorelin

FDA APPROVED

Growth Hormone

FDA-approved GHRH analog for visceral fat reduction in HIV lipodystrophy.

Sermorelin

FDA APPROVED

Growth Hormone

Truncated GHRH analog. Previously FDA-approved for pediatric GH deficiency.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.